Combinatorial biosynthesis - Potential and problems

被引:106
作者
Floss, Heinz G. [1 ]
机构
[1] Univ Washington, Dept Chem, Seattle, WA 98195 USA
关键词
combinatorial biosynthesis; metabolic engineering; natural products; rifamycin; maytansinoids; polyketides;
D O I
10.1016/j.jbiotec.2005.12.001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Because of their ecological functions, natural products have been optimized in evolution for interaction with biological systems and receptors. However, they have not necessarily been optimized for other desirable drug properties and thus can often be improved by structural modification. Using examples from the literature, this paper reviews the opportunities for increasing structural diversity among natural products by combinatorial biosynthesis, i.e., the genetic manipulation of biosynthetic pathways. It distinguishes between combinatorial biosynthesis in a narrower sense to generate libraries of modified structures, and metabolic engineering for the targeted formation of specific structural analogs. Some of the problems and limitations encountered with these approaches are also discussed. Work from the author's laboratory on ansamycin antibiotics is presented which illustrates some of the opportunities and limitations. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:242 / 257
页数:16
相关论文
共 53 条
[1]   The loading module of rifamycin synthetase is an adenylation-thiolation didomain with substrate tolerance for substituted benzoates [J].
Admiraal, SJ ;
Walsh, CT ;
Khosla, C .
BIOCHEMISTRY, 2001, 40 (20) :6116-6123
[2]   Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699 [J].
August, PR ;
Tang, L ;
Yoon, YJ ;
Ning, S ;
Muller, R ;
Yu, TW ;
Taylor, M ;
Hoffmann, D ;
Kim, CG ;
Zhang, XH ;
Hutchinson, CR ;
Floss, HG .
CHEMISTRY & BIOLOGY, 1998, 5 (02) :69-79
[3]   Bioactive microbial metabolites -: A personal view [J].
Bérdy, J .
JOURNAL OF ANTIBIOTICS, 2005, 58 (01) :1-26
[4]   MACROLIDE BIOSYNTHESIS .4. INTACT INCORPORATION OF A CHAIN-ELONGATION INTERMEDIATE INTO ERYTHROMYCIN [J].
CANE, DE ;
YANG, CC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1987, 109 (04) :1255-1257
[5]   Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis [J].
Carroll, BJ ;
Moss, SJ ;
Bai, LQ ;
Kato, Y ;
Toelzer, S ;
Yu, TW ;
Floss, HG .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (16) :4176-4177
[6]   Recent developments in the maytansinoid antitumor agents [J].
Cassady, JM ;
Chan, KK ;
Floss, HG ;
Leistner, E .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (01) :1-26
[7]  
Chari R.J., 1993, [No title captured], Patent No. 5208020
[8]  
Chari R. V. J., 2001, US Patent, Patent No. [6333410B1, 6333410]
[9]  
CHARI RVJ, 1992, CANCER RES, V52, P127
[10]   STOFFWECHSELPRODUKTE VON ACTINOMYCETEN .9. MITTEILUNG - GRANATICIN [J].
CORBAZ, R ;
ETTLINGER, L ;
GAUMANN, E ;
KALYODA, J ;
KELLERSCHIERLEIN, W ;
KRADOLFER, F ;
MANUKIAN, BK ;
NEIPP, L ;
PRELOG, V ;
REUSSER, P ;
ZAHNER, H .
HELVETICA CHIMICA ACTA, 1957, 40 (05) :1262-1269